NoPrescriptionDrugstore.US: FDA Clears The Fenwal Amicus(R) Separator System For Collecting Platelets In New Additive Solution

FDA Clears The Fenwal Amicus(R) Separator System For Collecting Platelets In New Additive Solution
Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced that the U.S. Food and Drug Administration has granted Fenwal 510(k) clearance to market its Amicus® blood cell separator for collecting human platelets stored in InterSol® platelet additive solution (PAS 3)...
Source: mnt.to

FDA Approves Exalgo™ Extended-Release Tablets
CombinatoRx, Incorporated (NASDAQ: CRXX) announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Exalgo™ (hydromorphone HCl) extended-release tablets, for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time...
Source: mnt.to

Health Dialog Offers Decision Aids For Men Considering Prostate Cancer Screening
Health Dialog, a leading provider of healthcare analytics and decision support, today announced that its decision support tools for prostate cancer screening have been made available for the month of March as a public service offering...
Source: mnt.to

FDA Clears biospace med's SterEOS 2D/3D Workstation For Pediatric Use In Spine
biospace med announced today that it has received 510(k) clearance from the FDA (Food and Drug Administration) to market the Company's sterEOS 2D/3D workstation for pediatric use in spine applications. The Company's EOS ultra-low-dose imager previously has been FDA-cleared for use in pediatrics and adults, while sterEOS has previously been FDA-cleared for adult use in spine...
Source: mnt.to

Play Yourself Healthy
A just published research experiment on inactive men with high blood pressure shows that just 3 months of soccer practise twice a week causes a significant fall in blood pressure, resting pulse rate, and percentage of body fat, and is more effective than the doctor's usual advice on healthy diet and exercise...
Source: mnt.to

ImmunoGen, Inc. Announces Orphan Drug Designation Granted To IMGN901 For Treatment Of Merkel Cell Carcinoma By US FDA And EU COMP
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its IMGN901 compound when used for the treatment of Merkel cell carcinoma (MCC)...
Source: mnt.to

# posted by Network @ 12:31 PM